Takeda gets ADZYNMA FDA approval for cTTP treatment: A new era in rare disease therapy
Takeda has achieved a monumental milestone in rare disease therapy with the U.S. Food and Drug Administration's approval of ADZYNMA (ADAMTS13, recombinant-krhn) for the treatment ... Read More
Takeda’s TAK-755 shows potential in Phase 3 trial for cTTP prophylaxis
Takeda Pharmaceutical Company has revealed promising interim results from its global Phase 3 trial of TAK-755, a recombinant ADAMTS13 protein in development for the prophylactic ... Read More